Pfizer to Control Cellectis in a €1.5 Billion Deal?

29/05/2015 - 2 minutes

Rumors are saying that French Cellectis is in talks about its potential sale. US-giant Pfizer is considered to be among the buyers.

According to The Financial Time, two people familiar with the situation said Cellectis was in negotiations over a deal, but warned no outcome was certain. The Financial Time also declared that “one person said Pfizer has approached the company about a deal that could value it at as much as €1.5 billion”. No information are suggesting that other parties are also in the sale talks with Cellectis.

Pfizer and Cellectis declined to comment this rumor but of course, the market reacts immediately with a 14% increase of Cellectis’ shares.

Last March, the French company, raised €200 million on the New York’s NASDAQ stock market, to continue the development of its CAR-T therapy, one of the hottest Biotech areas right now.

Cellectis intends to reprogrammed T-cells to make your own body immunized against cancer cells. To do so,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT Do you want to remove this advert? Become a member!
ADVERTISEMENT Do you want to remove this advert? Become a member!

Support Us

Become a Member